title: CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer.
authors.forename: James M
authors.initials: JM
authors.lastname: Rae
authors.forename: Meredith
authors.initials: M
authors.lastname: Regan
authors.forename: Brian
authors.initials: B
authors.lastname: Leyland-Jones
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Hayes
authors.forename: Mitch
authors.initials: M
authors.lastname: Dowsett
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D005260:Female; D006801:Humans; D017698:Postmenopause / Q000235:genetics*; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6